Please login to the form below

Not currently logged in
Email:
Password:

Tecentriq

This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.

Roche’s Tecentriq combo scores FDA approval for melanoma

Roche’s Tecentriq combo scores FDA approval for melanoma

The FDA approval of this Tecentriq combination represents an important step forward for many patients living with advanced melanoma," he added. ... This includes studies that are evaluating Tecentriq as a monotherapy and in combination with other

Latest news

  • Roche cites COVID-19 and biosimilars in Q2 decline Roche cites COVID-19 and biosimilars in Q2 decline

    Although sales of  Roche's newer drugs climbed by 37%, including haemophilia A treatment Hemlibra (emicizumab), multiple sclerosis therapy Ocrevus (ocrelizumab) and PD-1 inhibitor Tecentriq (atezolizumab), this was unable to

  • Tecentriq misses the mark in advanced ovarian cancer Tecentriq misses the mark in advanced ovarian cancer

    Tecentriq is part of a new class of immunotherapy treatments, also known as PD-1/L1 inhibitors, that have transformed the market over the last few years. ... The FDA approval for Imfinzi makes AZ’s drug the first PD-1/PD-L1 inhibitor to challenge

  • AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

    First checkpoint inhibitor to challenge Roche's Tecentriq in this indication. The FDA has approved AstraZeneca’s checkpoint inhibitor Imfinzi in combination with chemotherapy as a front-line treatment for ... Tecentriq’s US approval only covers

  • AZ’s Imfinzi plus tremelimumab combo misses again AZ’s Imfinzi plus tremelimumab combo misses again

    The data for Imfinzi is nevertheless still a plus overall for AZ as it allows it to challenge Roche’s PD-L1 inhibitor Tecentriq (atezolizumab), which was approved for first-line ... The data for Tecentriq and Imfinzi in extensive-stage SCLC look pretty

  • AstraZeneca’s Imfinzi fails first-line bladder cancer test AstraZeneca’s Imfinzi fails first-line bladder cancer test

    It also delays further competition to Roche’s rival PD-L1 inhibitor Tecentriq (atezolizumab), which became the first checkpoint inhibitor to be approved for first-line bladder cancer therapy in patients ... Last year, Roche also showed that Tecentriq

More from news
Approximately 60 fully matching, plus 80 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    It’s not all been plain sailing, with BMS’ Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... The drugmaker thinks Avastin may enhance

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Article: What's next? How behavioural science can support pharma's future
...
Video: UX/ Experience design research
...
White paper: The impact of COVID-19 on chronic disease management
...

Infographics